Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats
about
Ubiquitin-proteasome system involvement in Huntington's diseaseThe importance of integrating basic and clinical research toward the development of new therapies for Huntington diseaseMutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's diseaseReversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregationCorticostriatal Dysfunction in Huntington's Disease: The BasicsElusive roles for reactive astrocytes in neurodegenerative diseasesHuntington's disease: the past, present, and future search for disease modifiers.Transgenic animal models for study of the pathogenesis of Huntington's disease and therapyMouse models of polyglutamine diseases: review and data table. Part ITargeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseasesIntrabodies as neuroprotective therapeuticsMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Mutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 miceThe Wnt receptor Ryk reduces neuronal and cell survival capacity by repressing FOXO activity during the early phases of mutant huntingtin pathogenicityCognitive Training at a Young Age Attenuates Deficits in the zQ175 Mouse Model of HD.A broad phenotypic screen identifies novel phenotypes driven by a single mutant allele in Huntington's disease CAG knock-in mice.Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell modelA genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's diseaseGenetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesisDeletion of the triplet repeat encoding polyglutamine within the mouse Huntington's disease gene results in subtle behavioral/motor phenotypes in vivo and elevated levels of ATP with cellular senescence in vitroCharacterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging studyThe Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus.Deficits in a Simple Visual Go/No-go Discrimination Task in Two Mouse Models of Huntington's DiseaseSerine 421 regulates mutant huntingtin toxicity and clearance in mice.N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.Huntingtin is required for normal excitatory synapse development in cortical and striatal circuitsProteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis.Multiple phenotypes in Huntington disease mouse neural stem cells.A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesiImprovement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease.Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice.Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease miceForce-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease.Mouse models of Huntington's disease and methodological considerations for therapeutic trials.Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice.Large-scale phenome analysis defines a behavioral signature for Huntington's disease genotype in mice.Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease.Automated quantitative gait analysis in animal models of movement disorders.Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.Studies on the Q175 Knock-in Model of Huntington's Disease Using Functional Imaging in Awake Mice: Evidence of Olfactory Dysfunction
P2860
Q21129327-BB44D5AA-272B-49BC-8391-1082855B7EC8Q22306292-51FA9B0E-4E17-4B79-BB4E-6CFC96E02F34Q24317702-44EBEE0A-710A-4DE0-8526-7C4B1D907F4DQ24799882-2CCDF868-B233-45C4-A4FA-9F6A0C5E3A80Q26738379-D35F28AC-8F72-41BA-A2F8-5E549A46D670Q26797399-D79A1B07-1630-42A4-AB15-E7974DA4E597Q26830039-8C9B3926-A275-4360-8D2C-EA7672178FBBQ26849677-C36FD70D-D93A-4352-AE95-ACFEAC7E303BQ26853025-26EDA77C-B9A6-400B-85D4-773B081A54DFQ26859909-D8A512EB-8F3F-45F3-B1A5-D010ECA43F8DQ27003896-4AED8A77-8643-4D9E-9A0F-B2BD93ACDCE4Q27005950-240D96DE-BD5C-4AFF-97B2-29E05876E0D7Q27305680-B4404E3A-F433-4462-BA9D-EE32B8C86885Q27314681-9F3FB1BA-6942-42D3-9954-2983D3D24E23Q27321673-CEBF996D-436D-4094-8D35-94036D66725BQ28391627-B0328856-1361-4FFD-BD58-AF59B7AF002EQ28475537-27EF7B64-0112-4ECE-B324-E55DE81772C5Q28485362-A6985BEE-B532-4FF4-A71E-C2BAB66FDF0DQ28507529-E021BC41-0FF2-46F4-9747-0642B972764DQ28510315-DDFCF952-3BB4-433F-85AA-9E9E30904BD7Q28546047-82DD791F-6E49-42B8-9A2F-48ADE102D3D3Q28571426-A8688344-1DB8-49D7-87F2-83B21462BF6DQ28661598-5CD105AA-81F3-4E22-9D5C-E177184ACC5BQ30355064-4B7AF1E3-D47A-410A-8D58-D490908CADF4Q30358344-A9A2D956-0F28-440E-82F9-4110FE857BA5Q30408636-9B82461D-315D-4305-9F51-8E7BD0AC759FQ30418699-7A91FBC3-19D5-42C0-B2DD-D7C2A03ABB16Q30419653-480CD8C8-183B-461E-8A92-A86327DF2A22Q30423904-393A089F-DC95-46B1-B9BD-5791B2E83B46Q30426968-764426CE-4CBC-417A-B308-BFC87E1C984FQ30437121-B0D7616C-D997-4FE6-A441-2EF9F20C4F6CQ30437914-D78E0AC9-2D4F-40F7-A099-017F1E5E2856Q30452232-E5CE3145-00FD-4D5D-AE8B-42B5EDEDAB4CQ30481208-0E53ECCB-1B02-4DB5-84F2-1F3F1034C334Q30486668-2F592CF7-EBDF-4495-B39A-F3950467FB4DQ30489530-E31E9D38-0F1D-4583-95CE-F2984157B17EQ30490632-AA740297-784D-4084-8AFF-BE28E174549EQ30496179-6A69497C-7A32-44F6-8904-892D684A141AQ30501273-041BD421-F62C-4D52-85D4-D4DFB32A8270Q30581974-600862C3-CC00-4C85-851A-A014B00640EF
P2860
Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats
description
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2003
@ast
im Oktober 2003 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2003/10/06)
@sk
vědecký článek publikovaný v roce 2003
@cs
wetenschappelijk artikel (gepubliceerd op 2003/10/06)
@nl
наукова стаття, опублікована в жовтні 2003
@uk
مقالة علمية (نشرت في 6-10-2003)
@ar
name
Time course of early motor and ...... s disease with 140 CAG repeats
@ast
Time course of early motor and ...... s disease with 140 CAG repeats
@en
Time course of early motor and ...... s disease with 140 CAG repeats
@nl
type
label
Time course of early motor and ...... s disease with 140 CAG repeats
@ast
Time course of early motor and ...... s disease with 140 CAG repeats
@en
Time course of early motor and ...... s disease with 140 CAG repeats
@nl
prefLabel
Time course of early motor and ...... s disease with 140 CAG repeats
@ast
Time course of early motor and ...... s disease with 140 CAG repeats
@en
Time course of early motor and ...... s disease with 140 CAG repeats
@nl
P2093
P3181
P356
P1476
Time course of early motor and ...... s disease with 140 CAG repeats
@en
P2093
Ioannis Dragatsis
Jessica D. Sison
Liliana B. Menalled
Scott Zeitlin
P3181
P356
10.1002/CNE.10776
P407
P577
2003-10-06T00:00:00Z